A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
A phase 3 trial of Taletrectinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.
Overview
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT06564324 by Nuvation Bio Inc., with 194 participants planned, started 2024-11-27 and due to reach its primary completion in 2029-01. Interventions recorded: Taletrectinib, Crizotinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTaletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Shares Taletrectinib, Nuvation Bio, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Shares Taletrectinib, Nuvation Bio, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Shares Nuvation Bio, Non-small-cell lung cancer.
- TrialeXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Shares Crizotinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Crizotinib, Non-small-cell lung cancer.
- TrialA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Shares Crizotinib, Non-small-cell lung cancer.
- TargetRON receptor (MST1R)
Shares Crizotinib, Non-small-cell lung cancer.
- TreatmentCapmatinib
Shares Crizotinib, Non-small-cell lung cancer.